Current clinical use of 18FDG-PET/CT in patients with thoracic and systemic sarcoidosis

Radiologia Medica

Volumn 119, Issue 1, 2014, Pages 64-74

  Rubini, Giuseppe ^a   Cappabianca, Salvatore ^b   Altini, Corinna ^a   Notaristefano, Antonio ^a   Fanelli, Margherita ^a   Stabile Ianora, Amato Antonio ^a   Niccoli Asabella, Artor ^a   Rotondo, Antonio ^b  

^a UNIVERSITY OF BARI   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Follow up; MDCT; PET CT; Sarcoidosis

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BIOPSY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RETROSPECTIVE STUDY; SARCOIDOSIS; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898541664     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-013-0306-7     Document Type: Article

References (43)

1. Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Eng J Med 357:2153-2165
2. Cox CE, Davis-Allen A, Judson MA (2005) Sarcoidosis. Med Clin N Am 89:817-828
3. Dempsey OJ, Paterson EW, Kerr KM, Denison AR (2009) Sarcoidosis. BMJ 339:b3206
4. Prabhakar HB, Rabinowitz CB, Gibbons FK et al (2008) Imaging features of sarcoidosis on MDCT, FDG PET, and PET/CT. AJR Am J Roentgenol 190:S1-S6
5. Braun JJ, Kessler R, Constantinesco A, Imperiale A (2008) 18FFDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 35:1537-1543
6. Hunninghake GW, Costabel U, Ando M et al (1999) Statement on sarcoidosis. The Joint Statement of the American Thoracic Society, the European Respiratory Society, and the World Association of Sarcoidosis and Other Granulomatous Disorders adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160:736-755
7. Loehrl TA, Smith TL (2001) Inflammatory and granulomatous lesions of the larynx and pharynx. Am J Med 111:113S-117S
8. Reich JM, O'Connor EA, Brouns MC et al (1998) Mediastinoscopy in patients with presumptive stage I sarcoidosis: a risk/ benefit, cost/benefit analysis. Chest 113:147-153
9. Bradley B, Branley HM, Egan JJ, British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee, Thoracic Society of Australia, New Zealand Thoracic Society, Irish Thoracic Society et al (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63:v1-v58
10. Mimori Y (1998) Sarcoidosis: correlation of HRCT findings with results of pulmonary function tests and serum angiotensin converting enzyme assay. Kurume Med J 45:247-256
11. Hashimoto M, Watanabe O, Sato K et al (1996) The CT findings of pulmonary sarcoidosis. Tohoku J Exp Med 179:259-266
12. Abehsera M, Valeyere D, Grenier P (2000) Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 174:1751-1757
13. Koyama T, Ueda H, Togashi K et al (2004) Radiologic manifestations of sarcoidosis in various organs. Radiographics 24:87-104
14. Basu S, Saboury B, Werner T, Alavi A (2011) Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol 13:1051-1060
15. Kaira K, Ishizuka T, Yanagitani N et al (2007) Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med 32:114-116
16. Nguyen BD (2007) F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med 32:53-54
17. Nishiyama Y, Yamamoto Y, Fukunaga K et al (2006) Comparative evaluation of 18F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47:1571-1576
18. Alavi A, Gupta N, Alberini JL et al (2002) Positron emission tomography imaging in non malignant thoracic disorders. Semin Nucl Med 32:293-321
19. Alavi A, Buchpiguel CA, Loessner A (1994) Is there a role for FDG PET imaging in the management of patients with sarcoidosis? J Nucl Med 35:1650-1652
20. Brudin LH, Valind SO, Rhodes CG et al (1994) Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21:297-305
21. Alavi A, Palevsky HI (1992) Gallium-67-citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med 33:751-755
22. El-Haddad G, Zhuang H, Gupta N, Alavi A (2004) Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34:313-329
23. Koyama T, Ueda H, Togashi K et al (2004) Radiologic manifestations of sarcoidosis in various organs. Radiographics 24:87-104
24. Lewis PJ, Salama A (1994) Uptake of fluorine-18-Fluorodeoxyglucose in sarcoidosis. J Nucl Med 35:1647-1649
25. Aide N, Benayoun M, Kerrou K et al (2007) Impact of [18F]- flurodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 80:e67-e71
26. Zhao S, Kuge Y, Kohanawa M et al (2007) Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors. Eur J Nucl Med Mol Imaging 34:2096-2105
27. Ambrosini V, Fasano L, Zompatori M et al (2011) 18F-FDG PET/ CT detects systemic involvement in sarcoidosis. Eur J Nucl Med Mol Imaging 38:2102
28. Balan A, Hoey ET, Sheerin F et al (2010) Multi-technique imaging of sarcoidosis. Clin Radiol 65:750-760
29. Teirstein AS, Machac J, Almeida O et al (2007) Results of 188 whole-body fluorodeoxyglucose positron emission scans in 137 patients with sarcoidosis. Chest 132:1949-1953
30. Brauner MW, Lenoir S, Grenier P et al (1992) Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology 182:349-354
31. Murdoch J, Müller NL (1992) Pulmonary sarcoidosis: changes on follow-up CT examination. AJR Am J Roentgenol 159:473-477
32. Saito W, Kobayashi H, Shinkai M et al (2002) Pulmonary involvement in sarcoidosis: CT findings at diagnosis and their changes at follow-up in cases without corticosteroid treatment. Nihon Kokyuki Gakkai Zasshi 40:210-214
33. Leung AN, Brauner MW, Caillat-Vigneron N et al (1998) Sarcoidosis activity: correlation of HRCT findings with those of 67 Ga scanning, bronchoalveolar lavage, and serum angiotensinconverting enzyme assay. J Comput Assist Tomogr 22:229-234
34. Hansell DM, Milne DG, Wilsher ML, Wells AU (1998) Pulmonary sarcoidosis: morphologic associations of air flow obstruction at thin-section CT. Radiology 209:697-704
35. Bolat S, Berding G, Dengler R et al (2009) Fluorodeoxyglucose positron emission tomography (FDG PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257-259
36. Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV (2009) Sarcoid-like reaction to malignancy on 18F-FDG PET/CT: prevalence and disease pattern. Clin Radiol 64:675-681
37. Krüger S, Buck AK, Mottaghy FM et al (2008) Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging 32:269-273
38. Treglia G, Taralli S, Giordano A (2011) Emerging role of wholebody 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 28:87-94
39. Mostard RL, Vöö S, van Kroonenburgh MJ et al (2011) Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 105:1917-1924
40. Holzapfel K, Duetsch S, Gaa J et al (2009) Value of diffusionweighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 72:381-387
41. Brillet PY, Nunes H, Soussan M, Brauner MW (2011) Pulmonary sarcoidosis imaging. Rev Pneumol Clin 67:94-100
42. Mostard RL, Prompers L, Weijers RE et al (2012) F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 37:21-25
43. Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251:166-174